Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Cisapride did not play “significant” role in Ontario deaths, coroner says

Barbara Sibbald
CMAJ April 15, 2003 168 (8) 1035;
Barbara Sibbald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A coroner's investigation has determined there is “no conclusive evidence” that the antireflux drug cisapride played a significant role in the deaths of 7 patients at an Ontario hospital, but the pharmacist who reported the deaths to Health Canada remains unsatisfied.

Sana Sukkari, who works at Joseph Brant Memorial Hospital in Burlington, Ont., says she never expected conclusive evidence to emerge from the investigation, but she did expect it to recognize that the drug cisapride (Prepulsid) had been contraindicated for the patients and may have shortened their lives.

Although the results of coroner investigations are not released, families of the patients involved do receive a copy.

Dr. Ben Carruthers, the chief of staff at Joseph Brant, said the investigation hasn't resulted in any policy changes at the hospital. Existing safety mechanisms include having a pharmacist available for all patient care units, and computer programs that flag drug–drug interactions. Carruthers said cisapride use was standard practice at the time of the deaths.

Cisapride was also at the centre of a coroner's inquest into the death of Vanessa Young, 15, of Oakville, Ont., in March 2000 (CMAJ 2001;165[1]:1370). The drug, which was withdrawn from the market in August 2000, had been contraindicated for bulimic patients like Young, and for patients with heart disorders. The drug was linked to 80 deaths in Canada and the US.

According to the reports Sukkari filed with Health Canada, the 7 patients at Joseph Brant ranged in age from 54 to 84. Some were taking cisapride and cardiac medications that had been identified as having potentially dangerous interactions. All of the patients were extremely ill and receiving treatment in the hospital's intensive care unit. Sukkari remains convinced that the use of cisapride was “at least contributory in the outcomes of these 7 patients.”

Terrence Young, Vanessa Young's father and an outspoken advocate for reform of Canada's drug-approval system, supports that view. “The bottom line is that the drug was given when it shouldn't have been,” he said. — Barbara Sibbald, CMAJ

PreviousNext
Back to top

In this issue

CMAJ
Vol. 168, Issue 8
15 Apr 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cisapride did not play “significant” role in Ontario deaths, coroner says
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cisapride did not play “significant” role in Ontario deaths, coroner says
Barbara Sibbald
CMAJ Apr 2003, 168 (8) 1035;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Cisapride did not play “significant” role in Ontario deaths, coroner says
Barbara Sibbald
CMAJ Apr 2003, 168 (8) 1035;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Trudeau promises to boost federal health transfers when the pandemic is over
  • Does shaming have a place in public health?
  • Should Canada aim for #CovidZero?
Show more News

Similar Articles

Collections

  • Topics
    • Patient safety & quality improvement
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire